Abstract
Summary
The global cardiovascular market grew to US$89.7 billion in 2005, a
year-on-year increase of 9.6%.
The global cardiovascular market is forecast to expand to US$116.3 billion in
2010, equivalent to a CAGR of 5.3% over the next five years. The slow-down in
cardiovascular market growth between 2003 and 2005 is forecast to continue
through to 2010. While continued changes in demographics and lifestyle will
continue to drive cardiovascular sales forward, growth rates will be limited
by continued patent expiries for major products and a dearth of novel
therapies being introduced.
Cardiovascular Market Trends, 2007-2010 - Key market forecasts and
growth opportunities provides an in-depth analysis of the growing market for
pharmaceutical treatments for cardiovascular disorders including:
- Coronary heart disease
- Cerebrovascular disease
- Peripheral arterial disease
- Rheumatic heart disease
- Congenital heart disease
- Deep vein thrombosis and pulmonary embolism
This comprehensive report, from URCH Publishing, delivers market forecasts and
overviews to help inform you in your pharmaceutical business decision-making.
Key findings from the report include:
- The global market for cardiovascular patients will increase to 251 million
in 2010, with the greatest rate of growth forecast for the US market.
- The anti-hypertensives drug class dominates the global cardiovascular
market with a market share of nearly 50%.
- Of the top 20 products by global cardiovascular sales in 2005, all 20
generated annual sales in excess of US$1 billion.
- The top 20 products in 2005 contributed sales of US$59.3 billion
accounting for 66.1% of the total cardiovascular market.
- A total of 14 pharmaceutical companies were identified as having generated
cardiovascular sales in excess of US$1 billion in 2005.
- The leading cardiovascular drug projected to achieve the greatest growth
over the next five years is Takeda/ AstraZeneca' s Blopress/ Atacand
(candesartan) with a CAGR of 9.0%
This report provides key information needed in your business including:
- Sales forecast for top ten companies providing cardiovascular treatment
medicines.
- Analysis of leading cardiovascular products likely to loose patent
protection in the next ten years.
- Sales forecasts to 2010 for the top ten cardio medicines and forecasts by
drug class.
- Overview of disease incidence, areas of growth and breakdown of disease
burden and mortality.
- Breakdown of the major market trends and business opportunities
- In-depth coverage of the following companies' cardio market presence:
AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo,
GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi-Aventis, Servier.
Use This Report To:
- 1. Benchmark your company' s portfolio against market trends and forecasts
to plan better for greater profitability.
- 2. Indentify areas of potential pharmaceutical market growth and good
opportunities for delivering successful sales growth
- 3. Support your internal business planning processes by using an external
perspective founded on detailed analysis and solid market forecasts.
The 112 page publication contains 40 Figures and 46 Tables to help you make
sense of the wealth of data. This report will be of particular use to those
involved in:
- pharmaceutical company corporate planning,
- sales and marketing strategy,
- portfolio management, and,
- market and sales forecasting.
The report is divided into five key sections. Chapters 2-5 present historical
trends for key disease markets, key drug classes, key products and key
companies. Chapter 6 outlines future cardiovascular market trends and major
growth opportunities. The data and analysis contained within the report are
comprehensive, consistent and up-to-date and thus provide a single-point of
reference for understanding cardiovascular market trends.
| 
View Cart
